Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cytokinetics (CYTK) Shares Outstanding (Weighted Average): 2009-2024

Historic Shares Outstanding (Weighted Average) for Cytokinetics (CYTK) over the last 16 years, with Dec 2024 value amounting to $118.0 million.

  • Cytokinetics' Shares Outstanding (Weighted Average) rose 1.70% to $119.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $119.7 million, marking a year-over-year increase of 1.70%. This contributed to the annual value of $118.0 million for FY2024, which is 20.36% up from last year.
  • According to the latest figures from FY2024, Cytokinetics' Shares Outstanding (Weighted Average) is $118.0 million, which was up 20.36% from $98.1 million recorded in FY2023.
  • Over the past 5 years, Cytokinetics' Shares Outstanding (Weighted Average) peaked at $118.0 million during FY2024, and registered a low of $70.8 million during FY2020.
  • In the last 3 years, Cytokinetics' Shares Outstanding (Weighted Average) had a median value of $98.1 million in 2023 and averaged $103.6 million.
  • Data for Cytokinetics' Shares Outstanding (Weighted Average) shows a peak YoY increased of 20.36% (in 2024) over the last 5 years.
  • Over the past 5 years, Cytokinetics' Shares Outstanding (Weighted Average) (Yearly) stood at $70.8 million in 2020, then increased by 18.51% to $83.9 million in 2021, then increased by 12.81% to $94.6 million in 2022, then increased by 3.62% to $98.1 million in 2023, then climbed by 20.36% to $118.0 million in 2024.